Compare TPB & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPB | AGIO |
|---|---|---|
| Founded | 1988 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Tobacco | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2015 | 2013 |
| Metric | TPB | AGIO |
|---|---|---|
| Price | $89.93 | $28.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $115.00 | $38.88 |
| AVG Volume (30 Days) | 409.8K | ★ 856.8K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.39% | N/A |
| EPS Growth | ★ 45.33 | N/A |
| EPS | ★ 3.11 | N/A |
| Revenue | ★ $463,062,000.00 | $43,011,000.00 |
| Revenue This Year | $13.68 | $76.75 |
| Revenue Next Year | $11.32 | $170.73 |
| P/E Ratio | $28.72 | ★ N/A |
| Revenue Growth | ★ 28.39 | N/A |
| 52 Week Low | $65.80 | $22.24 |
| 52 Week High | $146.90 | $46.00 |
| Indicator | TPB | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 55.28 | 48.36 |
| Support Level | $83.01 | $26.42 |
| Resistance Level | $93.44 | $29.37 |
| Average True Range (ATR) | 4.50 | 0.95 |
| MACD | 0.29 | 0.16 |
| Stochastic Oscillator | 49.72 | 63.67 |
Turning Point Brands Inc operates as a manufacturer, marketer, and provider of consumer products that include Other Tobacco Products (OTP) in the U.S. The company offers a wide variety across the OTP spectrum, including moist snuff tobacco (MST), loose-leaf chewing tobacco, premium cigarette papers, make- your-own (MYO) cigar wraps, cigars, liquid vapor products, and tobacco vaporizer products. It operates in two segments, namely Zig-Zag products and Stoker's products segment. The company generates maximum revenue from the Zig-Zag products segment.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.